Table 1.
Patients demographics and clinical characteristics.
| Characteristic | No. | % |
|---|---|---|
| No. of patients | 151 | 100 |
| Age, median (range), y | 54 (19–71) | |
|
Gender Male Female |
83 68 |
55 45 |
|
MDS/MPN, WHO 2016 * MDS-MLD MDS-RS MDS-EB1 MDS-EB2 MDS-u CMML MPN (ET, CML) |
6 2 9 30 2 10 2 |
4 1 6 20 1 7 1 |
|
AML, WHO 2016 * AML with recurrent genetic abnormalities AML with MDS-related changes Therapy-related AML NOS Myeloid sarcoma Missing |
8 42 1 36 1 2 |
5 28 1 24 1 1 |
|
Karyotype Normal Aberrant Complex Monosomal Missing |
58 86 40 7 7 |
38 57 47 8 5 |
|
ELN Genetic Risk † Favorable Intermediate Adverse Missing |
8 44 37 1 |
9 49 41 1 |
|
Cytogenetic Risk ‡ Very good Good Intermediate Poor Very poor Missing |
0 24 5 13 5 2 |
0 49 10 27 10 4 |
|
Disease Status at allo-HSCT §/† Untreated Treated Remission CR1 CR2 PR No Remission Primary refractory Relapse Missing |
43 104 50 45 5 15 39 19 20 4 |
28 69 48 90 10 14 38 49 51 3 |
|
Conditioning || Standard-dose Dose-reduced |
54 97 |
36 64 |
|
Donor Type Matched related Matched unrelated Mismatched unrelated Haploidentical |
28 85 34 4 |
19 56 23 3 |
|
Graft source PBSC BM |
150 1 |
99 1 |
Note: * according to Arber et al. [18]; † according to ELN-criteria, Döhner et al. [19] (regarding AML patients, n = 90); ‡ according to IPSS-R, Greenberg et al. [20] (regarding MDS patients, n = 49); § according to Cheson et al. [21]; || according to Bacigalupo et al. [22]; allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; BM, bone marrow; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; CR1, first complete remission; CR2, second complete remission; ELN, European Leukemia Net; ET, essential thrombocythemia; IPSS-R, revised international prognostic scoring system; MDS, myelodysplastic syndrome; EB1, excess blasts 1; EB2, excess blasts 2; MDS-u, myelodysplastic syndrome-unclassifiable; MLD, multilineage dysplasia; MPN, myeloproliferative neoplasm; NOS, not otherwise specified; no., number; PBSC, peripheral blood stem cells; PR, partial remission; RS, ring sideroblasts; WHO, World Health Organization; y, years.